Literature DB >> 18712393

[Testicular tumors. Predictive factors].

G Mikuz1.   

Abstract

Patients with germ cell tumors of the testis can be given adjuvant treatment immediately after orchidectomy or put under surveillance with definitive treatment deferred until relapse. Both therapies are equally successful (success rate 98-99%), with surveillance alone, however, only approximately 50% of cases need toxic chemotherapy. The surveillance strategy is especially successful in patients with tumors which do not have morphological predictors of metastases. In seminomas the strongest predictor of metastases is tumor invasion of the rete testis followed by the size (Ø > or =4 cm) of the tumor. Vascular invasion, the most important predictor in non-seminomatous germ cell tumors, is less important in seminomas. The second most important predictor in mixed tumors is the presence or absence and the amount of embryonal carcinoma. The presence of teratomas and yolk sac tumors are considered to be predictors of a favorable course of the disease. The statistical impact of these markers is, however, not very strong. The only reliable predictor of malignancy of the gonadal stromal tumors is the size and tumors with a diameter > or =5 cm are always malignant.

Entities:  

Mesh:

Year:  2008        PMID: 18712393     DOI: 10.1007/s00292-008-1033-z

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  12 in total

1.  [Histopathologic risk factors in patients with non-seminomatous germ tumors of the testis in clinical stage 1. Retrospective study of 75 patients].

Authors:  A B Porcaro; S Zecchini Antoniolli; G Novella; G Martignoni; M A Bassetto; A Poli; D Schiavone; C Tallarigo; A D'Amico; V Ficarra; P Curti
Journal:  Arch Ital Urol Androl       Date:  2001-12

2.  Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone.

Authors:  L S Freedman; M C Parkinson; W G Jones; R T Oliver; M J Peckham; G Read; E S Newlands; C J Williams
Journal:  Lancet       Date:  1987-08-08       Impact factor: 79.321

3.  [Histopathologic and biological prognostic factors of clinical stage I non-seminomatous germ cell tumors. Implications for risk-adjusted therapy].

Authors:  A Heidenreich; I A Sesterhenn; F K Mostofi; J W Moul; U H Engelmann
Journal:  Urologe A       Date:  1999-03       Impact factor: 0.639

4.  Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors.

Authors:  R J Motzer; A Amsterdam; V Prieto; J Sheinfeld; V V Murty; M Mazumdar; G J Bosl; R S Chaganti; V E Reuter
Journal:  J Urol       Date:  1998-01       Impact factor: 7.450

5.  The prognostic significance of the tumour infiltrating lymphocyte count in stage I testicular seminoma managed by surveillance.

Authors:  C Parker; M Milosevic; T Panzarella; D Banerjee; M Jewett; C Catton; B Tew-George; M Gospodarowicz; P Warde
Journal:  Eur J Cancer       Date:  2002-10       Impact factor: 9.162

6.  Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study.

Authors:  Jorge Aparicio; José R Germà; Xavier García del Muro; Pablo Maroto; José A Arranz; Alberto Sáenz; Agustín Barnadas; Joan Dorca; Josep Gumà; David Olmos; Romá Bastús; Joan Carles; Daniel Almenar; Miguel Sánchez; Luis Paz-Ares; Juan J Satrústegui; Begoña Mellado; Ana Balil; Marta López-Brea; Alfredo Sánchez
Journal:  J Clin Oncol       Date:  2005-10-31       Impact factor: 44.544

Review 7.  Controversies in the management of clinical stage I testis cancer.

Authors:  Ronald de Wit; Karim Fizazi
Journal:  J Clin Oncol       Date:  2006-12-10       Impact factor: 44.544

8.  Long-term outcome of postorchiectomy surveillance for Stage I testicular seminoma.

Authors:  Richard Choo; Gillian Thomas; Tony Woo; David Lee; Brian Kong; Neil Iscoe; Cyril Danjoux; Laurie Klotz; Gerard Morton; Sarat Chander
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-03-01       Impact factor: 7.038

9.  Correlation between primary tumor pathologic features and presence of clinical metastasis at diagnosis of testicular seminoma.

Authors:  Juan P Valdevenito; Ivan Gallegos; Cristina Fernández; Cristian Acevedo; Rodrigo Palma
Journal:  Urology       Date:  2007-10       Impact factor: 2.649

Review 10.  European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I.

Authors:  Susanne Krege; Jörg Beyer; Rainer Souchon; Peter Albers; Walter Albrecht; Ferran Algaba; Michael Bamberg; István Bodrogi; Carsten Bokemeyer; Eva Cavallin-Ståhl; Johannes Classen; Christoph Clemm; Gabriella Cohn-Cedermark; Stéphane Culine; Gedske Daugaard; Pieter H M De Mulder; Maria De Santis; Maike de Wit; Ronald de Wit; Hans Günter Derigs; Klaus-Peter Dieckmann; Annette Dieing; Jean-Pierre Droz; Martin Fenner; Karim Fizazi; Aude Flechon; Sophie D Fosså; Xavier Garcia del Muro; Thomas Gauler; Lajos Geczi; Arthur Gerl; Jose Ramon Germa-Lluch; Silke Gillessen; Jörg T Hartmann; Michael Hartmann; Axel Heidenreich; Wolfgang Hoeltl; Alan Horwich; Robert Huddart; Michael Jewett; Johnathan Joffe; William G Jones; László Kisbenedek; Olbjørn Klepp; Sabine Kliesch; Kai Uwe Koehrmann; Christian Kollmannsberger; Markus Kuczyk; Pilar Laguna; Oscar Leiva Galvis; Volker Loy; Malcolm D Mason; Graham M Mead; Rolf Mueller; Craig Nichols; Nicola Nicolai; Tim Oliver; Dalibor Ondrus; Gosse O N Oosterhof; Luis Paz Ares; Giorgio Pizzocaro; Jörg Pont; Tobias Pottek; Tom Powles; Oliver Rick; Giovanni Rosti; Roberto Salvioni; Jutta Scheiderbauer; Hans-Ulrich Schmelz; Heinz Schmidberger; Hans-Joachim Schmoll; Mark Schrader; Felix Sedlmayer; Niels E Skakkebaek; Aslam Sohaib; Sergei Tjulandin; Padraig Warde; Stefan Weinknecht; Lothar Weissbach; Christian Wittekind; Eva Winter; Lori Wood; Hans von der Maase
Journal:  Eur Urol       Date:  2007-12-26       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.